Why Alnylam Pharmaceuticals, Inc. Competed Higher Today
May 26, 2016 at 15:55 PM EDT
What: Alnylam Pharmaceuticals is up 11% at 3:15 p.m. EDT after Alnylam's competitor Ionis Pharmaceuticals disclosed that its partner GlaxoSmithKline won't start a phase 3 clinical trial forIONIS-TTRRx in patients with transthyretin (TTR)-related amyloid cardiomyopathy.
